Photocarcinoma is one of the most common kinds of skin cancer caused by prolonged exposure to ultraviolet (UV) rays, necessitating innovative therapeutic approaches. Emerging strategies, including ribonucleic acid (RNA) therapy, immunotherapy, targeted therapy, and drug delivery by nanotechnology, are covered in this chapter. Among these, small interfering RNAs (siRNAs) and microRNAs (miRNAs) have been considered potential candidates for silencing oncogenes and manipulating tumor suppressor pathways. Likewise, immunotherapies can elicit possible immune-tumor cell reactions, for example, through the use of immune checkpoint inhibitors or adoptive cell therapies. Thus, improvements in treatment effectiveness and patient outcomes may result from combination regimens that employ chemotherapy, radiation, and immunotherapy. New targeted therapies against key molecular pathways, such as B-Raf proto-oncogene serine/threonine kinase (BRAF) and epidermal growth factor receptor (EGFR) inhibitors, are poised to change the landscape in precision oncology. Nanotechnology-driven drug delivery systems, like liposomes and polymeric nanoparticles, can improve bioavailability at target sites and minimize systemic toxicities. The integration of AI-assisted diagnostics can now enable early detection and more effective treatment planning. As research continues, leading-edge advances will definitively hold great promise for enhancing photocarcinoma management and, thus, improving both survival and quality of life in patients.